Atlas Trials

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

Clinical trial NCT07459673 · RECRUITING

Trial details

NCT number
NCT07459673
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerHER2-positive Breast CancerBreast Cancer Stage IV
Start date
2026-03-04
Primary completion
2030-03-04
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.